论文信息 - Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels. - 字舞流文

Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels.

[1] A. Gnanasakthy,et al. A review of patient-reported outcome labels in the United States: 2006 to 2010. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[2] Elizabeth Molsen,et al. Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[3] Ethan Basch,et al. The missing voice of patients in drug-safety reporting. , 2010, The New England journal of medicine.

[4] Elizabeth Molsen,et al. Multinational trials-recommendations on the translations required, approaches to using the same language in different countries, and the approaches to support pooling the data: the ISPOR Patient-Reported Outcomes Translation and Linguistic Validation Good Research Practices Task Force report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[5] A. Dupont,et al. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION , 1996 .